List view / Grid view
9 October 2014 | By The Controlled Release Alliance of Dow Pharma & Food Solutions
The Controlled Release Alliance of Dow Pharma & Food Solutions and Colorcon Inc. announced that it is planning to have global commercial availability of its next-generation METHOCEL™ DC2 polymer by year end...
9 October 2014 | By Bristol-Myers Squibb Company
Given the rapidly evolving hepatitis C treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue U.S. Food and Drug Administration approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States...
9 October 2014 | By Cambridge Healthtech Institute
Largest European event for protein and antibody engineering returns to Lisbon...
9 October 2014 | By On Broadcast
18 years since the first cord blood transplants were performed in the UK, public knowledge on this life-saving process is still sorely lacking. A study of over 4,000 people found that nearly a third (32%) of Britons did not know you can store umbilical cord blood and tissue, while the…
9 October 2014 | By kdm communications
Avacta’s Optim® 2 platform is an innovative analytical instrument designed to probe multiple protein stability indicating parameters at high speed using ultra-low sample volumes...
9 October 2014 | By kdm communications
Dolomite Microfluidics, a sister company to flow chemistry specialist Syrris, has developed an innovative range of Micro Droplet Systems for automatic, seamless production of monodispersed droplets...
8 October 2014 | By B&W Tek
B&W Tek, is pleased to announce new enhancements to its NanoRam® handheld Raman spectrometer...
8 October 2014 | By GlobalData
Gilead’s announcement of positive Phase III results for its investigational single-tablet regimen (STR), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (TAF), caps a series of developments bolstering the company’s position as HIV treatment market leader...
8 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva (efavirenz) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) products...
8 October 2014 | By The Wellcome Trust, The Institute of Cancer Research & Merck Serono
Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family...
8 October 2014 | By Allied Minds
Allied Minds announced the launch of Novare Pharmaceuticals, a biotechnology company focused on developing therapeutic products that help the body replenish and rebuild itself using its own tissue through the modulation of RHAMM...
8 October 2014 | By OBN and EMIG
OBN and EMIG have called on the UK government to allocate additional funding to support the industrial component of Innovate UK’s Biomedical Catalyst...
8 October 2014 | By Ubiquigent and University of Dundee
Agreement brings together expertise to design, develop and market small molecule libraries targeting ubiquitin system proteins...
7 October 2014 | By Medical Research Council
Three ambitious new research programmes, which aim to deliver a step-change in our understanding of disease by using human volunteers in experimental studies, have been funded as part of a £60m investment from the Medical Research Council...
7 October 2014 | By Embo Medical
Early-stage medical device company is developing minimally invasive embolization technology for the treatment of wide variety of diseases...
